These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

666 related articles for article (PubMed ID: 16440307)

  • 1. Antisense applications for biological control.
    Pan WH; Clawson GA
    J Cell Biochem; 2006 May; 98(1):14-35. PubMed ID: 16440307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNAzymes as potential therapeutic molecules.
    Isaka Y
    Curr Opin Mol Ther; 2007 Apr; 9(2):132-6. PubMed ID: 17458166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxicology of antisense therapeutics.
    Jason TL; Koropatnick J; Berg RW
    Toxicol Appl Pharmacol; 2004 Nov; 201(1):66-83. PubMed ID: 15519609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RNAi: a novel antisense technology and its therapeutic potential.
    Dallas A; Vlassov AV
    Med Sci Monit; 2006 Apr; 12(4):RA67-74. PubMed ID: 16572063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic oligonucleotides.
    Goodchild J
    Methods Mol Biol; 2011; 764():1-15. PubMed ID: 21748630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antisense treatments for biothreat agents.
    Warfield KL; Panchal RG; Aman MJ; Bavari S
    Curr Opin Mol Ther; 2006 Apr; 8(2):93-103. PubMed ID: 16610760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent developments in oligonucleotide conjugation.
    Singh Y; Murat P; Defrancq E
    Chem Soc Rev; 2010 Jun; 39(6):2054-70. PubMed ID: 20393645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Making sense of antisense.
    Vidal L; Blagden S; Attard G; de Bono J
    Eur J Cancer; 2005 Dec; 41(18):2812-8. PubMed ID: 16289851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of gene expression by targeted disruption of messenger RNA: available options and current strategies.
    Jen KY; Gewirtz AM
    Stem Cells; 2000; 18(5):307-19. PubMed ID: 11007915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sugar boost: when ribose modifications improve oligonucleotide performance.
    Faria M; Ulrich H
    Curr Opin Mol Ther; 2008 Apr; 10(2):168-75. PubMed ID: 18386229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antisense inhibitors, ribozymes, and siRNAs.
    Thompson AJ; Patel K
    Clin Liver Dis; 2009 Aug; 13(3):375-90. PubMed ID: 19628155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonviral in vivo delivery of therapeutic small interfering RNAs.
    Aigner A
    Curr Opin Mol Ther; 2007 Aug; 9(4):345-52. PubMed ID: 17694447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Innovative nanotechnologies for the delivery of oligonucleotides and siRNA.
    Toub N; Malvy C; Fattal E; Couvreur P
    Biomed Pharmacother; 2006 Nov; 60(9):607-20. PubMed ID: 16952435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nucleic-acid therapeutics: basic principles and recent applications.
    Opalinska JB; Gewirtz AM
    Nat Rev Drug Discov; 2002 Jul; 1(7):503-14. PubMed ID: 12120257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antisense strategies in degenerative joint diseases: sense or nonsense?
    Huber LC; Distler O; Gay RE; Gay S
    Adv Drug Deliv Rev; 2006 May; 58(2):285-99. PubMed ID: 16574269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel integrated strategy (full length gene targeting) for mRNA accessible site tagging combined with microarray hybridization/RNase H cleavage to screen effective antisense oligonucleotides.
    Sun Y; Duan M; Lin R; Wang D; Li C; Bo X; Wang S
    Mol Vis; 2006 Nov; 12():1364-71. PubMed ID: 17149362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hammerhead ribozymes: biochemical and chemical considerations.
    Goodchild J
    Curr Opin Mol Ther; 2000 Jun; 2(3):272-81. PubMed ID: 11249621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ribozymes, DNAzymes and small interfering RNAs as therapeutics.
    Sioud M; Iversen PO
    Curr Drug Targets; 2005 Sep; 6(6):647-53. PubMed ID: 16178798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Locked nucleoside analogues expand the potential of DNAzymes to cleave structured RNA targets.
    Vester B; Hansen LH; Lundberg LB; Babu BR; Sørensen MD; Wengel J; Douthwaite S
    BMC Mol Biol; 2006 Jun; 7():19. PubMed ID: 16753066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identifying accessible sites in RNA: the first step in designing antisense reagents.
    Pan WH; Clawson GA
    Curr Med Chem; 2006; 13(25):3083-103. PubMed ID: 17073649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.